HOME >> BIOLOGY >> NEWS
24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

re subjects discontinued LPV/r due to AEs (6 percent) than 908/rQD or 908/r BID (both <1 percent).

Likewise, Grade 3-4 lab abnormalities were similar between all three treatment arms, and all regimens had minimal impact on plasma lipids. The incidence of Grade 3-4 lipid abnormalities was low. No subject experienced a Grade 3-4 elevation in cholesterol, whereas elevated triglyceride levels occurred in 8 percent of patients taking 908/r BID (n=8,) versus 4 percent of patients taking 908/r QD (n=4) or LPV/r BID (n=4). Mean fasting cholesterol levels for all three study groups remained below the recommended National Cholesterol Education Program (NCEP) intervention guidelines.

Study Demographics

The study population comprised patients enrolled from 103 centers in 13 countries worldwide. Approximately 16 percent of patients enrolled in CONTEXT are female, and the age range of all patients is 24 72 years (median 41 years). Sixty-seven percent of patients are Caucasian, 24 percent are of African descent and 9 percent are Hispanic. Criteria for entry into the study included treatment-experienced patients with current failure of antiretroviral therapy. To enroll in the CONTEXT trial, patients had to have a screening viral load >1,000 copies/mL and no active or acute Category C events (indicative of AIDS disease) according to guidelines established by the Centers for Disease Control and Prevention.

Summary of Clinical Trials with 908

More than 1,200 people have participated in three Phase III trials to test the safety and efficacy of 908: NEAT, SOLO and CONTEXT. The SOLO study was an open-label trial with 649 HIV+, treatment-nave patients. Participants were randomized to receive either 1400 mg of 908 plus 200 mg ritonavir (908/r) QD or 1250 mg of nelfinavir BID. All also received the two NRTIs, ABC and 3TC. The trial, conducted at more than 100 research centers worldwide, was designed to assess the safety and efficacy of each
'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
14-Feb-2003


Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/5/2018)... Ill. (PRWEB) , ... October ... ... Edwardsville, in partnership with the University of Illinois Extension and Monroe County ... Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) Non-Land ...
(Date:10/5/2018)... ... 04, 2018 , ... Nothing brings a team together like cooking and eating ... , Cooking appeals to companies because it encourages a range of healthy activities that ... skills. It’s also appealing in that everyone – no matter their culinary ability ...
(Date:10/2/2018)... ... 02, 2018 , ... Stem Cell Innovations (SCI), a global network of professionals ... therapy, has launched the pre-sale for their ICO with participants purchasing SCIA ... connect patients and stem cell specialists around the world. , SCI (formally ...
Breaking Biology News(10 mins):
(Date:10/5/2018)... WILMINGTON, N.C. (PRWEB) , ... October 04, 2018 ... ... announced today that it has received a Spine Technology Award from Orthopedics This ... Angeles, CA last week. The Power T Handle is a surgical instrument that ...
(Date:10/5/2018)... (PRWEB) , ... October 04, 2018 , ... ... an Anacortes, Wash.-based nonprofit, with a grant to purchase a high-tech machine that ... that washes ashore in Washington State. The organization then processes the usable plastic ...
(Date:10/3/2018)... (PRWEB) , ... October 03, 2018 , ... Milwaukee Area ... open house Wednesday, Oct. 17, from 3-7 p.m. in Room T129 in the T ... to its new CNC Swiss Lab. A ribbon cutting and formal program will be ...
(Date:10/2/2018)... ... October 02, 2018 , ... Finalists for the 2018 ... AssurEOR product line was chosen for its advancements in the production chemicals category. ... innovations in upstream oil applications that are positively impacting the industry. The winners ...
Breaking Biology Technology:
Cached News: